SEC Form 10-Q filed by Shuttle Pharmaceuticals Holdings Inc.
$SHPH
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
8-K - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Filer)
4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)
4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)
3 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)
United Dogecoin looks to have its miners operational within approximately 60 days, leveraging low-cost, renewable energy, on its path to being the market's largest Dogecoin miner by hashrateGaithersburg, Maryland--(Newsfile Corp. - June 26, 2026) - United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining company driven by industry experts recently acquired by Shuttle Pharmaceutical Holdings, Inc. (NASDAQ:SHPH) ("Shuttle"), has completed two significant milestones on its projected path to market scale and operational excellence.United Dogecoin has purchased its first fleet of ElphaPex DG1+ mining units, which the Company believes are among the most powerful and efficient D
United Dogecoin shares insights on its digital infrastructure strategy, aimed at expanding revenue opportunities and supporting long-term shareholder value creation.Gaithersburg, Maryland--(Newsfile Corp. - June 25, 2026) - United Dogecoin Inc. ("United Dogecoin" or the "Company"), a Dogecoin mining and digital infrastructure company driven by industry experts recently acquired by Shuttle Pharmaceutical Holdings, Inc. (NASDAQ:SHPH) ("Shuttle"), has initiated an evaluation of proprietary data centre and power generation opportunities designed to support long-term DOGE mining operations and future AI infrastructure workloads. Alongside this exploration, the Company continues to move toward ele
Initial Mining Fleet Targeted for Deployment Within 60 Days of Receipt; To Mine DOGE and LTC and Accumulate Mined Coins as Long-Term Treasury AssetsGaithersburg, Maryland--(Newsfile Corp. - May 14, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced the closing (the "Closing") of its previously announced merger with United Dogecoin Inc. ("United Dogecoin"), and the confirmation of a purchase order granting the Company the option to purchase up to 3,000 next-generation ElphaPex Scrypt mining rigs ("Mining Rigs") for use in the Company's Dogecoin (DOGE) and Litecoin (LTC) merge-mining operations. As previously reported on Shuttle's Current R
4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)
4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)
4 - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Issuer)
Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle" or the "Company") today announced that it has closed the acquisition of the assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.Under the terms of the agreement, 1563868 B.C. Ltd., a wholly owned subsidiary of Shuttle, acquired substantially all of Molecule's assets and liabilities for a total purchase price of $8 million, payable in a combination of cash and shares of Shuttle common stock, plus an additional contingent $2 million, pay
GAITHERSBURG, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of George Scorsis as the Chairman of the Board of Directors. Mr. Scorsis has served as director of the Company since February 2025. Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks, and Biotech. From October 2015 to July 2017, Mr. Scorsis worked as President at Mettrum Heal
GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of Christopher Cooper as interim Co-Chief Executive Officer focused on enhancing the Company's capital markets and business capabilities. Dr. Anatoly Dritschilo, Chairman of the Company's Board of Directors, will continue in his role as Co-CEO overseeing the Company's scientific and clinical trial activities. "I am excited to welcome Christopher Cooper as Co-CEO of
SC 13G/A - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)
SC 13G - Shuttle Pharmaceuticals Holdings, Inc. (0001757499) (Subject)